Completed NA INTERVENTIONAL 1-arm NCT02659254

A First-in-Man Study of the Firesorb BVS (FUTURE-I) (FUTURE-I)

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-I

Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.

Conditions Coronary Artery Disease

Interventions Sirolimus Target Eluting Bioresorbable Vascular Scaffold

Updated 8 times since 2017 Last updated: Oct 23, 2023 Started: Jan 31, 2016 Primary completion: May 31, 2016 Completion: Mar 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Coronary Artery Disease and is currently completed. Shanghai MicroPort Medical (Group) Co., Ltd. leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Nov 2023 — Jul 2024 [monthly]

Completed NA

Status: Unknown Status → Completed
Nov 2021 — Nov 2023 [monthly]

Unknown Status NA

Status: Active Not Recruiting → Unknown Status

▶ Show 3 earlier versions

Jan 2021 — Nov 2021 [monthly]

Active Not Recruiting NA
Jun 2018 — Jan 2021 [monthly]

Active Not Recruiting NA
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting NA

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai MicroPort Medical (Group) Co., Ltd.

Data source: Shanghai MicroPort Medical (Group) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China